newsfilter
← Latest News
GlobeNewswire·

Eliem Therapeutics Provides ETX-810 Program Update

SEATTLE and CAMBRIDGE, United Kingdom, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in